The pre-seed investment was completed across two tranches to support the scale of the company's bootcamp model.
"At Ufi, we continue to be enthused by the unique learner proposition at CAPSLOCK, enabling learners to access skills needed for work in high demand sectors in the UK, such as Cyber Security, whilst removing the upfront financial barriers to training, through their innovative Income Share Agreement model."
Ascension VC led the seed round to support the expansion of the social impact platform.
"At the heart of hundo is a belief that it is possible to scale an agile solution that empowers young people to own their future through decent, paid employment that is the basic foundation for them to build their lives from. Ultimately, young people will be able to learn, work and earn online through the hundo platform wherever they are in the world."
The Series A round was led by Makers Fund and Lightspeed Venture Partners to support team expansion and technology development.
"We’re thrilled to see investors’ excitement for AudioMob’s vision for long term success and our future. We’re on the precipice of innovating a whole industry with audio and now we’re able to build out our tech and team to ensure we’re disrupting the industry in the right way and ensure we eventually become a future tech industry unicorn."
Vita Spring provided the funding as QuantuMDx also pursues commercialisation discussions with Sansure Biotech.
"I am very pleased to announce this equity investment today which will enable us to further evolve the Q-POC™ platform, making our system one of the most innovative, high multiplexing, molecular point of care devices in the market. Vita Spring shares our mission of developing accurate and efficient solutions to identify pathogens and diagnose diseases and so we are delighted they have chosen to invest in QuantuMDx. We are also looking forward to our close future relationship with Sansure and believe they will be an excellent partner for QuantuMDx in China as we look to increase our global footprint in Chinese and adjacent markets."
— Jonathan O’Halloran, Co-founder and Chief Executive
The seed round was backed by investors including Firstminute Capital, Presight Capital, and Seedcamp.
"Traditional clinical research companies are dinosaurs. Taking part in a COVID vaccine trial was like stepping into a time machine. This was one of the best funded trials in history but research was done on pen and paper and participants had to go into hospital at the height of the pandemic to fill out forms. We founded Lindus Health to make it easier for patients to participate in research, and accelerate the development of new treatments."